JP2014521591A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014521591A5 JP2014521591A5 JP2013554574A JP2013554574A JP2014521591A5 JP 2014521591 A5 JP2014521591 A5 JP 2014521591A5 JP 2013554574 A JP2013554574 A JP 2013554574A JP 2013554574 A JP2013554574 A JP 2013554574A JP 2014521591 A5 JP2014521591 A5 JP 2014521591A5
- Authority
- JP
- Japan
- Prior art keywords
- carbon atoms
- branched
- optionally substituted
- cell
- linear
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000004432 carbon atoms Chemical group C* 0.000 claims 73
- 150000001875 compounds Chemical class 0.000 claims 44
- 125000003342 alkenyl group Chemical group 0.000 claims 35
- 125000000304 alkynyl group Chemical group 0.000 claims 31
- 150000001768 cations Chemical class 0.000 claims 29
- 125000005647 linker group Chemical group 0.000 claims 29
- 229910052757 nitrogen Inorganic materials 0.000 claims 28
- 125000000217 alkyl group Chemical group 0.000 claims 27
- 239000011780 sodium chloride Substances 0.000 claims 27
- 150000001413 amino acids Chemical class 0.000 claims 24
- 150000003839 salts Chemical class 0.000 claims 23
- 210000004027 cells Anatomy 0.000 claims 21
- 229920001223 polyethylene glycol Chemical group 0.000 claims 21
- 229910052760 oxygen Inorganic materials 0.000 claims 19
- 239000002202 Polyethylene glycol Chemical group 0.000 claims 18
- 125000003827 glycol group Chemical group 0.000 claims 18
- 125000005842 heteroatoms Chemical group 0.000 claims 18
- 102000004965 antibodies Human genes 0.000 claims 17
- 108090001123 antibodies Proteins 0.000 claims 17
- -1 etc.) Chemical compound 0.000 claims 17
- 229910052717 sulfur Inorganic materials 0.000 claims 17
- 125000000623 heterocyclic group Chemical group 0.000 claims 16
- 229910052799 carbon Inorganic materials 0.000 claims 13
- 201000010099 disease Diseases 0.000 claims 13
- 125000001072 heteroaryl group Chemical group 0.000 claims 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 12
- 230000001472 cytotoxic Effects 0.000 claims 11
- 231100000433 cytotoxic Toxicity 0.000 claims 11
- 229910052736 halogen Inorganic materials 0.000 claims 10
- 150000002367 halogens Chemical class 0.000 claims 10
- 229910052698 phosphorus Inorganic materials 0.000 claims 9
- ZRALSGWEFCBTJO-UHFFFAOYSA-O guanidinium Chemical compound NC(N)=[NH2+] ZRALSGWEFCBTJO-UHFFFAOYSA-O 0.000 claims 8
- YNAVUWVOSKDBBP-UHFFFAOYSA-N morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 8
- 229940113083 morpholine Drugs 0.000 claims 8
- NQRYJNQNLNOLGT-UHFFFAOYSA-N piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 8
- RWRDLPDLKQPQOW-UHFFFAOYSA-N pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 8
- 241000124008 Mammalia Species 0.000 claims 7
- 239000002131 composite material Substances 0.000 claims 7
- 125000006242 amine protecting group Chemical group 0.000 claims 6
- 125000003118 aryl group Chemical group 0.000 claims 6
- 230000004663 cell proliferation Effects 0.000 claims 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims 6
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 6
- 102000005614 monoclonal antibodies Human genes 0.000 claims 6
- 108010045030 monoclonal antibodies Proteins 0.000 claims 6
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims 6
- 239000001301 oxygen Substances 0.000 claims 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 6
- 239000011593 sulfur Substances 0.000 claims 6
- 206010025323 Lymphomas Diseases 0.000 claims 5
- 150000002148 esters Chemical class 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 125000004043 oxo group Chemical group O=* 0.000 claims 5
- 125000003107 substituted aryl group Chemical group 0.000 claims 5
- 206010000880 Acute myeloid leukaemia Diseases 0.000 claims 4
- 206010020243 Hodgkin's disease Diseases 0.000 claims 4
- 201000006743 Hodgkin's lymphoma Diseases 0.000 claims 4
- 208000007046 Leukemia, Myeloid, Acute Diseases 0.000 claims 4
- 206010025310 Other lymphomas Diseases 0.000 claims 4
- FDDDEECHVMSUSB-UHFFFAOYSA-N Sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 claims 4
- 239000002246 antineoplastic agent Substances 0.000 claims 4
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide Chemical compound [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 claims 4
- 239000011230 binding agent Substances 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 201000009910 diseases by infectious agent Diseases 0.000 claims 4
- 229920001184 polypeptide Polymers 0.000 claims 4
- WTKZEGDFNFYCGP-UHFFFAOYSA-N pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims 4
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 claims 4
- 125000001424 substituent group Chemical group 0.000 claims 4
- 229960001663 sulfanilamide Drugs 0.000 claims 4
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 4
- 150000003457 sulfones Chemical class 0.000 claims 4
- 125000001302 tertiary amino group Chemical group 0.000 claims 4
- 206010003816 Autoimmune disease Diseases 0.000 claims 3
- 208000001083 Kidney Disease Diseases 0.000 claims 3
- 208000000429 Leukemia, Lymphocytic, Chronic, B-Cell Diseases 0.000 claims 3
- 208000000748 Leukemia, Prolymphocytic, T-Cell Diseases 0.000 claims 3
- 206010053643 Neurodegenerative disease Diseases 0.000 claims 3
- 210000002997 Osteoclasts Anatomy 0.000 claims 3
- 206010033616 Pancreatic disease Diseases 0.000 claims 3
- NMHMNPHRMNGLLB-UHFFFAOYSA-N Phloretic acid Chemical compound OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 claims 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 3
- 206010042985 T-cell prolymphocytic leukaemia Diseases 0.000 claims 3
- 208000001756 Virus Disease Diseases 0.000 claims 3
- 230000002159 abnormal effect Effects 0.000 claims 3
- 125000004429 atoms Chemical group 0.000 claims 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 3
- 230000003176 fibrotic Effects 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 201000009251 multiple myeloma Diseases 0.000 claims 3
- 230000002148 osteoclast Effects 0.000 claims 3
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 claims 3
- 125000005330 8 membered heterocyclic group Chemical group 0.000 claims 2
- 206010000871 Acute monocytic leukaemia Diseases 0.000 claims 2
- 208000009899 Burkitt Lymphoma Diseases 0.000 claims 2
- 206010008958 Chronic lymphocytic leukaemia Diseases 0.000 claims 2
- 206010012818 Diffuse large B-cell lymphoma Diseases 0.000 claims 2
- 206010018651 Graft versus host disease Diseases 0.000 claims 2
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 2
- 208000009721 Leukemia, Monocytic, Acute Diseases 0.000 claims 2
- 208000008456 Leukemia, Myelogenous, Chronic, BCR-ABL Positive Diseases 0.000 claims 2
- 208000006557 Lymphoma, B-Cell, Marginal Zone Diseases 0.000 claims 2
- 206010029461 Nodal marginal zone B-cell lymphomas Diseases 0.000 claims 2
- 208000007452 Plasmacytoma Diseases 0.000 claims 2
- KZNICNPSHKQLFF-UHFFFAOYSA-N Succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 claims 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-L Sulphite Chemical compound [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 claims 2
- 206010042971 T-cell lymphoma Diseases 0.000 claims 2
- 101710040533 TNFRSF8 Proteins 0.000 claims 2
- 102100009538 TNFRSF8 Human genes 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 201000006966 adult T-cell leukemia Diseases 0.000 claims 2
- 125000005466 alkylenyl group Chemical group 0.000 claims 2
- 150000001412 amines Chemical class 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 108091007172 antigens Proteins 0.000 claims 2
- 102000038129 antigens Human genes 0.000 claims 2
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-M bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims 2
- KWEDUNSJJZVRKR-UHFFFAOYSA-N carbononitridic azide Chemical compound [N-]=[N+]=NC#N KWEDUNSJJZVRKR-UHFFFAOYSA-N 0.000 claims 2
- 108091006028 chimera Proteins 0.000 claims 2
- 201000006934 chronic myeloid leukemia Diseases 0.000 claims 2
- 125000004122 cyclic group Chemical group 0.000 claims 2
- NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 claims 2
- WBZKQQHYRPRKNJ-UHFFFAOYSA-L disulfite Chemical compound [O-]S(=O)S([O-])(=O)=O WBZKQQHYRPRKNJ-UHFFFAOYSA-L 0.000 claims 2
- 229940017705 formaldehyde sulfoxylate Drugs 0.000 claims 2
- 201000009277 hairy cell leukemia Diseases 0.000 claims 2
- SBGKURINHGJRFN-UHFFFAOYSA-N hydroxymethanesulfinic acid Chemical compound OCS(O)=O SBGKURINHGJRFN-UHFFFAOYSA-N 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- PEEHTFAAVSWFBL-UHFFFAOYSA-N maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 2
- 125000006501 nitrophenyl group Chemical group 0.000 claims 2
- 229960002317 succinimide Drugs 0.000 claims 2
- 150000003462 sulfoxides Chemical class 0.000 claims 2
- DHCDFWKWKRSZHF-UHFFFAOYSA-L thiosulfate(2-) Chemical compound [O-]S([S-])(=O)=O DHCDFWKWKRSZHF-UHFFFAOYSA-L 0.000 claims 2
- 125000001917 2,4-dinitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C(=C1*)[N+]([O-])=O)[N+]([O-])=O 0.000 claims 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims 1
- 208000009746 Adult T-Cell Leukemia-Lymphoma Diseases 0.000 claims 1
- 206010002449 Angioimmunoblastic T-cell lymphoma Diseases 0.000 claims 1
- 208000003950 B-Cell Lymphoma Diseases 0.000 claims 1
- 206010073480 B-cell prolymphocytic leukaemia Diseases 0.000 claims 1
- 101710042656 BQ2027_MB1231C Proteins 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 206010067184 Burkitt's leukaemia Diseases 0.000 claims 1
- 102100005826 CD19 Human genes 0.000 claims 1
- 101700087100 CD19 Proteins 0.000 claims 1
- 102100000189 CD22 Human genes 0.000 claims 1
- 101700020617 CD22 Proteins 0.000 claims 1
- 102100016493 CD33 Human genes 0.000 claims 1
- 101700017647 CD33 Proteins 0.000 claims 1
- 102100016530 CD37 Human genes 0.000 claims 1
- 101700044364 CD37 Proteins 0.000 claims 1
- 102100003279 CD38 Human genes 0.000 claims 1
- 101700044948 CD38 Proteins 0.000 claims 1
- 102100013077 CD4 Human genes 0.000 claims 1
- 101700022938 CD4 Proteins 0.000 claims 1
- 102100013137 CD40 Human genes 0.000 claims 1
- 101710040446 CD40 Proteins 0.000 claims 1
- 101700078950 CD44 Proteins 0.000 claims 1
- 102100003735 CD44 Human genes 0.000 claims 1
- 102100005834 CD6 Human genes 0.000 claims 1
- 101700067044 CD6 Proteins 0.000 claims 1
- 201000004085 CLL/SLL Diseases 0.000 claims 1
- 241000189662 Calla Species 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 claims 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 claims 1
- 102100010782 EGFR Human genes 0.000 claims 1
- 101700039191 EGFR Proteins 0.000 claims 1
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims 1
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims 1
- 206010061850 Extranodal marginal zone B-cell lymphoma (MALT type) Diseases 0.000 claims 1
- 102000006815 Folate receptors Human genes 0.000 claims 1
- 108020005243 Folate receptors Proteins 0.000 claims 1
- 206010017758 Gastric cancer Diseases 0.000 claims 1
- 208000005017 Glioblastoma Diseases 0.000 claims 1
- 102000009465 Growth Factor Receptors Human genes 0.000 claims 1
- 108010009202 Growth Factor Receptors Proteins 0.000 claims 1
- 208000005209 Hematologic Disease Diseases 0.000 claims 1
- 206010066957 Hepatosplenic T-cell lymphoma Diseases 0.000 claims 1
- 201000007012 Hodgkin's lymphoma, lymphocytic-histiocytic predominance Diseases 0.000 claims 1
- 229940088597 Hormone Drugs 0.000 claims 1
- 206010061598 Immunodeficiency Diseases 0.000 claims 1
- 102000018358 Immunoglobulins Human genes 0.000 claims 1
- 108060003951 Immunoglobulins Proteins 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- 210000000822 Killer Cells, Natural Anatomy 0.000 claims 1
- 208000006404 Large Granular Lymphocytic Leukemia Diseases 0.000 claims 1
- 206010024324 Leukaemias Diseases 0.000 claims 1
- 208000001152 Leukemia, Prolymphocytic, B-Cell Diseases 0.000 claims 1
- 206010025135 Lupus erythematosus Diseases 0.000 claims 1
- 210000002751 Lymph Anatomy 0.000 claims 1
- 208000003747 Lymphoid Leukemia Diseases 0.000 claims 1
- 102000008072 Lymphokines Human genes 0.000 claims 1
- 108010074338 Lymphokines Proteins 0.000 claims 1
- 208000003002 Lymphoma, T-Cell, Peripheral Diseases 0.000 claims 1
- 208000007282 Lymphomatoid Papulosis Diseases 0.000 claims 1
- 206010025327 Lymphopenia Diseases 0.000 claims 1
- 206010061232 Lymphoproliferative disease Diseases 0.000 claims 1
- 201000003791 MALT lymphoma Diseases 0.000 claims 1
- 108090000028 MMP12 Proteins 0.000 claims 1
- 102100000165 MS4A1 Human genes 0.000 claims 1
- 101710010909 MS4A1 Proteins 0.000 claims 1
- 206010025650 Malignant melanoma Diseases 0.000 claims 1
- 206010026798 Mantle cell lymphomas Diseases 0.000 claims 1
- 210000002752 Melanocytes Anatomy 0.000 claims 1
- 208000002030 Merkel Cell Carcinoma Diseases 0.000 claims 1
- 102100007544 NCAM1 Human genes 0.000 claims 1
- 101700077124 NCAM1 Proteins 0.000 claims 1
- 210000004693 NK cell Anatomy 0.000 claims 1
- 206010028811 Natural killer-cell leukaemia Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 102000003729 Neprilysin Human genes 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 claims 1
- 206010029592 Non-Hodgkin's lymphomas Diseases 0.000 claims 1
- 208000002154 Non-Small-Cell Lung Carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 208000000814 Primary Cutaneous Anaplastic Large Cell Lymphoma Diseases 0.000 claims 1
- 206010065857 Primary effusion lymphoma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010039073 Rheumatoid arthritis Diseases 0.000 claims 1
- 208000009359 Sezary Syndrome Diseases 0.000 claims 1
- 201000006984 Sezary's disease Diseases 0.000 claims 1
- 208000000587 Small Cell Lung Carcinoma Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 206010062113 Splenic marginal zone lymphoma Diseases 0.000 claims 1
- 206010041823 Squamous cell carcinoma Diseases 0.000 claims 1
- 210000001744 T-Lymphocytes Anatomy 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 210000001541 Thymus Gland Anatomy 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 208000009999 Tuberous Sclerosis Diseases 0.000 claims 1
- 229940029983 VITAMINS Drugs 0.000 claims 1
- 229940021016 Vitamin IV solution additives Drugs 0.000 claims 1
- 206010047802 Waldenstrom's macroglobulinaemias Diseases 0.000 claims 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims 1
- 201000005510 acute lymphocytic leukemia Diseases 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 210000002798 bone marrow cell Anatomy 0.000 claims 1
- 201000005216 brain cancer Diseases 0.000 claims 1
- 201000011231 colorectal cancer Diseases 0.000 claims 1
- 230000003013 cytotoxicity Effects 0.000 claims 1
- 231100000135 cytotoxicity Toxicity 0.000 claims 1
- 230000003247 decreasing Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000003444 follicular lymphoma Diseases 0.000 claims 1
- 230000002538 fungal Effects 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 201000008064 heavy chain disease Diseases 0.000 claims 1
- 201000005787 hematologic cancer Diseases 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 230000000527 lymphocytic Effects 0.000 claims 1
- 201000006439 lymphocytic leukemia Diseases 0.000 claims 1
- 231100001023 lymphopenia Toxicity 0.000 claims 1
- 201000000564 macroglobulinemia Diseases 0.000 claims 1
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 201000005962 mycosis fungoide Diseases 0.000 claims 1
- 201000002481 myositis Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 125000000538 pentafluorophenyl group Chemical group FC1=C(F)C(F)=C(*)C(F)=C1F 0.000 claims 1
- 108010091867 peptide P Proteins 0.000 claims 1
- 201000007923 peripheral T-cell lymphoma Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 201000006845 reticulosarcoma Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 230000001228 trophic Effects 0.000 claims 1
- 210000004881 tumor cells Anatomy 0.000 claims 1
- 239000011782 vitamin Substances 0.000 claims 1
- 235000013343 vitamin Nutrition 0.000 claims 1
- 229930003231 vitamins Natural products 0.000 claims 1
- 0 CC(C1CCC(CN(C(CC2C*)=O)C2=O)CC1)=O Chemical compound CC(C1CCC(CN(C(CC2C*)=O)C2=O)CC1)=O 0.000 description 5
- URZDOFJAENAVIT-UHFFFAOYSA-N CC(CCOCCNC(C)=O)=O Chemical compound CC(CCOCCNC(C)=O)=O URZDOFJAENAVIT-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161443062P | 2011-02-15 | 2011-02-15 | |
| US201161443092P | 2011-02-15 | 2011-02-15 | |
| US61/443,062 | 2011-02-15 | ||
| US61/443,092 | 2011-02-15 | ||
| US201161483499P | 2011-05-06 | 2011-05-06 | |
| US61/483,499 | 2011-05-06 | ||
| PCT/US2012/025252 WO2012128868A1 (en) | 2011-02-15 | 2012-02-15 | Cytotoxic benzodiazepine derivatives |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015202619A Division JP6216356B2 (ja) | 2011-02-15 | 2015-10-14 | 細胞傷害性ベンゾジアゼピン誘導体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014521591A JP2014521591A (ja) | 2014-08-28 |
| JP2014521591A5 true JP2014521591A5 (US07714131-20100511-C00001.png) | 2015-04-02 |
| JP5826863B2 JP5826863B2 (ja) | 2015-12-02 |
Family
ID=45755579
Family Applications (8)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013554574A Active JP5826863B2 (ja) | 2011-02-15 | 2012-02-15 | 細胞傷害性ベンゾジアゼピン誘導体 |
| JP2013554575A Active JP6049642B2 (ja) | 2011-02-15 | 2012-02-15 | 複合体の調製方法 |
| JP2015202619A Expired - Fee Related JP6216356B2 (ja) | 2011-02-15 | 2015-10-14 | 細胞傷害性ベンゾジアゼピン誘導体 |
| JP2017182007A Active JP6526138B2 (ja) | 2011-02-15 | 2017-09-22 | 細胞傷害性ベンゾジアゼピン誘導体 |
| JP2019082629A Active JP6703632B2 (ja) | 2011-02-15 | 2019-04-24 | 細胞傷害性ベンゾジアゼピン誘導体 |
| JP2020082654A Pending JP2020143102A (ja) | 2011-02-15 | 2020-05-08 | 細胞傷害性ベンゾジアゼピン誘導体 |
| JP2021167884A Pending JP2022009073A (ja) | 2011-02-15 | 2021-10-13 | 細胞傷害性ベンゾジアゼピン誘導体 |
| JP2023201247A Pending JP2024026207A (ja) | 2011-02-15 | 2023-11-29 | 細胞傷害性ベンゾジアゼピン誘導体 |
Family Applications After (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013554575A Active JP6049642B2 (ja) | 2011-02-15 | 2012-02-15 | 複合体の調製方法 |
| JP2015202619A Expired - Fee Related JP6216356B2 (ja) | 2011-02-15 | 2015-10-14 | 細胞傷害性ベンゾジアゼピン誘導体 |
| JP2017182007A Active JP6526138B2 (ja) | 2011-02-15 | 2017-09-22 | 細胞傷害性ベンゾジアゼピン誘導体 |
| JP2019082629A Active JP6703632B2 (ja) | 2011-02-15 | 2019-04-24 | 細胞傷害性ベンゾジアゼピン誘導体 |
| JP2020082654A Pending JP2020143102A (ja) | 2011-02-15 | 2020-05-08 | 細胞傷害性ベンゾジアゼピン誘導体 |
| JP2021167884A Pending JP2022009073A (ja) | 2011-02-15 | 2021-10-13 | 細胞傷害性ベンゾジアゼピン誘導体 |
| JP2023201247A Pending JP2024026207A (ja) | 2011-02-15 | 2023-11-29 | 細胞傷害性ベンゾジアゼピン誘導体 |
Country Status (30)
Families Citing this family (158)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1789391B1 (en) | 2004-07-23 | 2017-06-28 | Endocyte, Inc. | Bivalent linkers and conjugates thereof |
| EP1928503B1 (en) | 2005-08-24 | 2012-10-03 | ImmunoGen, Inc. | Process for preparing maytansinoid antibody conjugates |
| US9138484B2 (en) | 2007-06-25 | 2015-09-22 | Endocyte, Inc. | Conjugates containing hydrophilic spacer linkers |
| US9877965B2 (en) | 2007-06-25 | 2018-01-30 | Endocyte, Inc. | Vitamin receptor drug delivery conjugates for treating inflammation |
| SG173152A1 (en) | 2009-02-05 | 2011-08-29 | Immunogen Inc | Novel benzodiazepine derivatives |
| PL2437790T3 (pl) | 2009-06-03 | 2019-09-30 | Immunogen, Inc. | Sposoby sprzęgania |
| KR101671360B1 (ko) | 2010-04-15 | 2016-11-01 | 시애틀 지네틱스, 인크. | 표적화된 피롤로벤조디아제핀 접합체 |
| WO2011130616A1 (en) | 2010-04-15 | 2011-10-20 | Spirogen Limited | Pyrrolobenzodiazepines used to treat proliferative diseases |
| EP3666289A1 (en) * | 2011-02-15 | 2020-06-17 | ImmunoGen, Inc. | Cytotoxic benzodiazepine derivatives |
| KR20220123130A (ko) * | 2011-03-29 | 2022-09-05 | 이뮤노젠 아이엔씨 | 일-단계 방법에 의한 메이탄시노이드 항체 접합체의 제조 |
| CN103987718A (zh) | 2011-09-20 | 2014-08-13 | 斯皮罗根有限公司 | 作为非对称二聚体pbd化合物用于内含在靶向结合物中的吡咯并苯并二氮杂卓 |
| EA028457B1 (ru) | 2011-10-14 | 2017-11-30 | Медимьюн Лимитед | Пирролобензодиазепины |
| EA036202B1 (ru) | 2011-10-14 | 2020-10-14 | Сиэтл Дженетикс, Инк. | Пирролбензодиазепины и конъюгаты направленного действия |
| EP3388435B1 (en) | 2011-10-14 | 2023-05-03 | Seagen Inc. | Pyrrolobenzodiazepines and targeted conjugates |
| BR112014008981A2 (pt) | 2011-10-14 | 2017-05-02 | Spirogen Sàrl | pirrolobenzodiazepinas |
| EP2793949B1 (en) | 2011-12-23 | 2018-08-22 | Innate Pharma | Enzymatic conjugation of antibodies |
| CA2869704A1 (en) * | 2012-04-04 | 2013-10-10 | Perseus Proteomics Inc. | Drug conjugate comprising anti-cdh3 (pcadherin) antibody |
| US9504756B2 (en) | 2012-05-15 | 2016-11-29 | Seattle Genetics, Inc. | Self-stabilizing linker conjugates |
| KR20230113821A (ko) | 2012-05-15 | 2023-08-01 | 씨젠 인크. | 자가-안정화 링커 접합체 |
| EP2872894B1 (en) | 2012-07-13 | 2019-04-17 | Innate Pharma | Screening of conjugated antibodies |
| EP2887965A1 (en) * | 2012-08-22 | 2015-07-01 | ImmunoGen, Inc. | Cytotoxic benzodiazepine derivatives |
| SG11201502429YA (en) | 2012-10-04 | 2015-04-29 | Immunogen Inc | Use of a pvdf membrane to purify cell-binding agent cytotoxic agent conjugates |
| EP2906250B1 (en) | 2012-10-12 | 2018-05-30 | ADC Therapeutics SA | Pyrrolobenzodiazepine-anti-psma antibody conjugates |
| WO2014057120A1 (en) * | 2012-10-12 | 2014-04-17 | Adc Therapeutics Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
| WO2014057118A1 (en) * | 2012-10-12 | 2014-04-17 | Adc Therapeutics Sarl | Pyrrolobenzodiazepine-anti-cd22 antibody conjugates |
| KR101986404B1 (ko) | 2012-10-12 | 2019-06-07 | 에이디씨 테라퓨틱스 에스에이 | 피롤로벤조디아제핀-항체 컨주게이트 |
| SI2906298T1 (sl) * | 2012-10-12 | 2018-12-31 | Adc Therapeutics Sa | Konjugati pirolobenzodiazepin-protitelo |
| PT2906296T (pt) * | 2012-10-12 | 2018-06-01 | Medimmune Ltd | Conjugados de pirrolobenzodiazepina-anticorpo |
| AU2013328580B2 (en) | 2012-10-12 | 2016-01-21 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| WO2014057072A1 (en) | 2012-10-12 | 2014-04-17 | Spirogen Sàrl | Synthesis and intermediates of pyrrolobenzodiazepine derivatives for conjugation |
| SI2906251T1 (en) * | 2012-10-12 | 2018-01-31 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-anti-CD22 antibody conjugates |
| NZ705910A (en) | 2012-10-12 | 2018-09-28 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| EP2916872B1 (en) | 2012-11-09 | 2019-02-27 | Innate Pharma | Recognition tags for tgase-mediated conjugation |
| JP2016500058A (ja) * | 2012-11-12 | 2016-01-07 | レッドウッド バイオサイエンス， インコーポレイテッド | 化合物および抱合体を生成するための方法 |
| US9353150B2 (en) | 2012-12-04 | 2016-05-31 | Massachusetts Institute Of Technology | Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment |
| MY169117A (en) | 2012-12-21 | 2019-02-18 | Bioalliance Cv | Hydrophilic self-immolative linkers and conjugates thereof |
| CN105246894A (zh) * | 2012-12-21 | 2016-01-13 | 斯皮罗根有限公司 | 用于治疗增殖性和自身免疫疾病的非对称吡咯并苯并二氮杂卓二聚物 |
| EP2935268B2 (en) | 2012-12-21 | 2021-02-17 | MedImmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| ES2843786T3 (es) | 2013-03-13 | 2021-07-20 | Seagen Inc | Filtración con carbono activado para la purificación de ADC de benzodiazepina |
| NZ710745A (en) | 2013-03-13 | 2019-03-29 | Genentech Inc | Pyrrolobenzodiazepines and conjugates thereof |
| EA201591710A1 (ru) | 2013-03-13 | 2016-03-31 | Сиэтл Дженетикс, Инк. | Композиции, содержащие циклодекстрин и конъюгат антитело-лекарственное средство |
| US9649390B2 (en) | 2013-03-13 | 2017-05-16 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| EP2968582B1 (en) | 2013-03-15 | 2020-07-01 | Innate Pharma | Solid phase tgase-mediated conjugation of antibodies |
| EP3010547B1 (en) | 2013-06-20 | 2021-04-21 | Innate Pharma | Enzymatic conjugation of polypeptides |
| CN105517577A (zh) | 2013-06-21 | 2016-04-20 | 先天制药公司 | 多肽的酶促偶联 |
| US10208125B2 (en) | 2013-07-15 | 2019-02-19 | University of Pittsburgh—of the Commonwealth System of Higher Education | Anti-mucin 1 binding agents and uses thereof |
| AU2014312215B2 (en) | 2013-08-28 | 2020-02-27 | Abbvie Stemcentrx Llc | Site-specific antibody conjugation methods and compositions |
| SG11201601416VA (en) | 2013-08-28 | 2016-03-30 | Stemcentrx Inc | Novel sez6 modulators and methods of use |
| BR112016004073A8 (pt) * | 2013-08-28 | 2018-06-12 | Stemcentrx Inc | Anticorpos criados por engenharia, conjugados de anticorpo fármaco, seu método de preparação e seu uso, composição farmacêutica e seu uso, kits, e métodos para administrar uma pirrolobenzodiazepina (pbd) a uma célula de câncer que expressa dll3 e para determinar a citotoxicidade de um conjugado de anticorpo fármaco anti-dll3 |
| WO2015028850A1 (en) * | 2013-09-02 | 2015-03-05 | Hangzhou Dac Biotech Co., Ltd | Novel cytotoxic agents for conjugation of drugs to cell binding molecule |
| EP3054985B1 (en) | 2013-10-11 | 2018-12-26 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
| US9956299B2 (en) | 2013-10-11 | 2018-05-01 | Medimmune Limited | Pyrrolobenzodiazepine—antibody conjugates |
| GB201317981D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
| WO2015052532A1 (en) | 2013-10-11 | 2015-04-16 | Spirogen Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
| CN105764503A (zh) | 2013-10-15 | 2016-07-13 | 西雅图基因公司 | 用于改善配体-药物偶联物药代动力学的peg化的药物-接头 |
| CA2938450C (en) | 2014-02-11 | 2023-10-17 | Seattle Genetics, Inc. | Selective reduction of proteins |
| EP3107576A4 (en) | 2014-02-21 | 2017-09-06 | Abbvie Stemcentrx LLC | Anti-dll3 antibodies and drug conjugates for use in melanoma |
| US10550190B2 (en) * | 2014-04-04 | 2020-02-04 | Merck Sharp & Dohme Corp. | Phosphate based linkers for intracellular delivery of drug conjugates |
| BR112016026730A2 (pt) * | 2014-05-20 | 2017-12-12 | Immunogen Inc | métodos de caracterização e tratamento de leucemia mieloide aguda |
| WO2015196167A1 (en) | 2014-06-20 | 2015-12-23 | Bioalliance C.V. | Anti-folate receptor aplha (fra) antibody-drug conjugates and methods of using thereof |
| WO2016008112A1 (en) | 2014-07-16 | 2016-01-21 | Medshine Discovery Inc. | Linkers and application towards adc thereof |
| CA2958882A1 (en) * | 2014-09-02 | 2016-03-10 | Immunogen, Inc. | Methods for formulating antibody drug conjugate compositions |
| EP3189057A1 (en) | 2014-09-03 | 2017-07-12 | ImmunoGen, Inc. | Cytotoxic benzodiazepine derivatives |
| JP2017529837A (ja) | 2014-09-03 | 2017-10-12 | イミュノジェン・インコーポレーテッド | 細胞結合剤及び細胞毒性剤を含む複合体 |
| CA2959630A1 (en) | 2014-09-03 | 2016-03-10 | Immunogen, Inc. | Cytotoxic benzodiazepine derivatives |
| GB201416112D0 (en) * | 2014-09-12 | 2014-10-29 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| AU2015314954B2 (en) | 2014-09-12 | 2021-05-13 | Genentech, Inc. | Anti-HER2 antibodies and immunoconjugates |
| KR20170055521A (ko) | 2014-09-17 | 2017-05-19 | 제넨테크, 인크. | 항-her2 항체를 포함하는 면역콘주게이트 |
| GB201419108D0 (en) | 2014-10-27 | 2014-12-10 | Glythera Ltd | Materials and methods relating to linkers for use in antibody drug conjugates |
| EP3220959A1 (en) * | 2014-11-19 | 2017-09-27 | ImmunoGen, Inc. | Process for preparing cell-binding agent-cytotoxic agent conjugates |
| CN107148285B (zh) | 2014-11-25 | 2022-01-04 | Adc治疗股份有限公司 | 吡咯并苯并二氮杂䓬-抗体缀合物 |
| MX2017007641A (es) * | 2014-12-09 | 2017-10-02 | Abbvie Inc | Conjugados de anticuerpo-farmaco con inhibidores de bcl-xl permeables en las celulas. |
| US10766959B2 (en) | 2014-12-11 | 2020-09-08 | Pierre Fabre Medicament | Anti-C10ORF54 antibodies and uses thereof |
| JP6676058B2 (ja) | 2015-01-14 | 2020-04-08 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | ヘテロアリーレン架橋したベンゾジアゼピン二量体、そのコンジュゲート、ならびに製造および使用方法 |
| CA2973354A1 (en) | 2015-01-14 | 2016-07-21 | Bristol-Myers Squibb Company | Benzodiazepine dimers, conjugates thereof, and methods of making and using |
| CA2979527A1 (en) * | 2015-03-13 | 2016-09-22 | Endocyte, Inc. | Conjugates of pyrrolobenzodiazepine (pbd) prodrugs for treating disease |
| WO2016149313A1 (en) | 2015-03-17 | 2016-09-22 | Arrowhead Research Corporation | Improved disulfide-containing alkyne linking agents |
| US9504694B2 (en) | 2015-03-19 | 2016-11-29 | Cellerant Therapeutics, Inc. | Isoquinolidinobenzodiazepines |
| GB201506411D0 (en) | 2015-04-15 | 2015-05-27 | Bergenbio As | Humanized anti-axl antibodies |
| GB201506402D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
| EA039619B1 (ru) * | 2015-05-20 | 2022-02-17 | Иммуноджен, Инк. | Способ получения индолинобензодиазепиновых соединений |
| GB201510010D0 (en) | 2015-06-09 | 2015-07-22 | King S College London | PDD and BPD compounds |
| US9688694B2 (en) | 2015-06-23 | 2017-06-27 | Bristol-Myers Squibb Company | Macrocyclic benzodiazepine dimers, conjugates thereof, preparation and uses |
| RU2739612C2 (ru) * | 2015-06-29 | 2020-12-28 | Иммуноджен, Инк. | Анти-cd123 антитела и их конъюгаты и производные |
| MA42250B1 (fr) * | 2015-06-29 | 2020-11-30 | Immunogen Inc | Conjugués d'anticorps à cystéine modifiée |
| PL3325482T3 (pl) | 2015-07-21 | 2021-01-11 | Immunogen, Inc. | Sposoby otrzymywania cytotoksycznych pochodnych benzodiazepiny |
| GB201514928D0 (en) | 2015-08-21 | 2015-10-07 | King S College London | PDD compounds |
| US20180339985A1 (en) | 2015-08-21 | 2018-11-29 | Femtogenix Limited | Pdd compounds |
| MA43345A (fr) * | 2015-10-02 | 2018-08-08 | Hoffmann La Roche | Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation |
| EP4335851A3 (en) * | 2015-11-25 | 2024-06-05 | ImmunoGen, Inc. | Pharmaceutical formulations and methods of use thereof |
| TWI753875B (zh) | 2016-01-08 | 2022-02-01 | 美商美國全心醫藥生技股份有限公司 | 四價抗psgl-1抗體及其用途 |
| GB201601431D0 (en) | 2016-01-26 | 2016-03-09 | Medimmune Ltd | Pyrrolobenzodiazepines |
| RU2018130108A (ru) * | 2016-02-05 | 2020-03-06 | Иммуноджен, Инк. | Эффективный способ получения конъюгатов связывающийся с клеткой агент цитотоксический агент |
| SG11201806142WA (en) * | 2016-02-05 | 2018-08-30 | Millennium Pharm Inc | Gcc-targeted antibody-drug conjugates |
| GB201602356D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| GB201602359D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| CN109843919A (zh) | 2016-03-25 | 2019-06-04 | 西雅图基因公司 | 用于制备聚乙二醇化的药物-接头及其中间体的方法 |
| US20200323991A1 (en) * | 2016-03-29 | 2020-10-15 | Endocyte, Inc. | Pbd conjugates for treating diseases |
| KR102295190B1 (ko) * | 2016-04-20 | 2021-08-30 | 항저우 디에이씨 바이오테크 씨오, 엘티디 | 아마니타 독소의 유도체 및 세포 결합 분자와의 그것의 결합 |
| EP3454864A4 (en) | 2016-04-21 | 2021-01-13 | Abbvie Stemcentrx LLC | NOVEL ANTI-BMPR1B ANTIBODIES AND METHOD OF USING |
| GB201607478D0 (en) | 2016-04-29 | 2016-06-15 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| WO2017197045A1 (en) | 2016-05-11 | 2017-11-16 | Movassaghi Mohammad | Convergent and enantioselective total synthesis of communesin analogs |
| WO2017201132A2 (en) | 2016-05-18 | 2017-11-23 | Mersana Therapeutics, Inc. | Pyrrolobenzodiazepines and conjugates thereof |
| WO2017223275A1 (en) | 2016-06-24 | 2017-12-28 | Mersana Therapeutics, Inc. | Pyrrolobenzodiazepines and conjugates thereof |
| CN109562152B (zh) | 2016-08-09 | 2024-04-02 | 西雅图基因公司 | 含有具有改善的生理化学性质的自稳定性接头的药物缀合物 |
| GB201617466D0 (en) | 2016-10-14 | 2016-11-30 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
| CN110300600A (zh) | 2016-11-02 | 2019-10-01 | 伊缪诺金公司 | 利用抗体-药物缀合物和parp抑制剂的组合治疗 |
| CN110072890B (zh) * | 2016-11-03 | 2022-11-29 | 百时美施贵宝公司 | 可活化的抗ctla-4抗体及其用途 |
| EP3544983A2 (en) * | 2016-11-23 | 2019-10-02 | Immunogen, Inc. | Selective sulfonation of benzodiazepine derivatives |
| JP7244987B2 (ja) | 2016-12-14 | 2023-03-23 | シージェン インコーポレイテッド | 多剤抗体薬物コンジュゲート |
| US20210388102A1 (en) | 2016-12-23 | 2021-12-16 | Immunogen, Inc. | Immunoconjugates targeting adam9 and methods of use thereof |
| TW201825515A (zh) | 2017-01-04 | 2018-07-16 | 美商伊繆諾金公司 | Ｍｅｔ抗體以及其免疫結合物及用途 |
| CN118772276A (zh) | 2017-01-24 | 2024-10-15 | 依奈特制药公司 | Nkp46结合剂 |
| SG11201906666QA (en) | 2017-01-25 | 2019-08-27 | Immunogen Inc | Methods of preparing cytotoxic benzodiazepine derivatives |
| WO2018141959A1 (en) | 2017-02-06 | 2018-08-09 | Innate Pharma | Immunomodulatory antibody drug conjugates binding to a human mica polypeptide |
| GB201702031D0 (en) | 2017-02-08 | 2017-03-22 | Medlmmune Ltd | Pyrrolobenzodiazepine-antibody conjugates |
| CA3047683C (en) | 2017-02-08 | 2020-03-10 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
| IL269398B2 (en) | 2017-03-24 | 2024-05-01 | Seagen Inc | A process for the preparation of glucuronide-drug binders and their intermediates |
| WO2018183494A1 (en) | 2017-03-31 | 2018-10-04 | Immunogen, Inc. | Cd19-targeting antibody-drug conjugates |
| LT3612537T (lt) | 2017-04-18 | 2022-10-10 | Medimmune Limited | Pirolobenzodiazepino konjugatai |
| CN106841192B (zh) * | 2017-04-18 | 2019-05-03 | 乐凯（沈阳）科技产业有限责任公司 | 一种二氮杂卓结构指示剂检测甲醛方法及其应用 |
| BR112019021880A2 (pt) | 2017-04-20 | 2020-06-02 | Adc Therapeutics Sa | Terapia de combinação com conjugado anticorpo anti-axl-droga |
| WO2018195243A1 (en) | 2017-04-20 | 2018-10-25 | Immunogen, Inc. | Cytotoxic benzodiazepine derivatives and conjugates thereof |
| TWI790228B (zh) * | 2017-04-20 | 2023-01-21 | 美商伊繆諾金公司 | 製備吲哚啉苯并二氮平衍生物之方法 |
| WO2018209239A1 (en) | 2017-05-11 | 2018-11-15 | Massachusetts Institute Of Technology | Potent agelastatin derivatives as modulators for cancer invasion and metastasis |
| US11318211B2 (en) | 2017-06-14 | 2022-05-03 | Adc Therapeutics Sa | Dosage regimes for the administration of an anti-CD19 ADC |
| WO2019018892A1 (en) | 2017-07-26 | 2019-01-31 | The University Of Queensland | COMPOUNDS CONTAINING DISULFIDE BOND AND USES THEREOF |
| LT3668874T (lt) | 2017-08-18 | 2022-03-25 | Medimmune Limited | Pirolobenzodiazepino konjugatai |
| IL301637B2 (en) | 2017-09-29 | 2024-10-01 | Daiichi Sankyo Co Ltd | Conjugation of an antibody with a pyrrolobenzodiazepine derivative |
| US10640508B2 (en) | 2017-10-13 | 2020-05-05 | Massachusetts Institute Of Technology | Diazene directed modular synthesis of compounds with quaternary carbon centers |
| WO2019089594A1 (en) | 2017-10-31 | 2019-05-09 | Immunogen, Inc. | Combination treatment with antibody-drug conjugates and cytarabine |
| WO2019092148A1 (en) | 2017-11-10 | 2019-05-16 | Innate Pharma | Antibodies with functionalized glutamine residues |
| EP3717021A1 (en) | 2017-11-27 | 2020-10-07 | Mersana Therapeutics, Inc. | Pyrrolobenzodiazepine antibody conjugates |
| TWI827575B (zh) | 2017-12-28 | 2024-01-01 | 美商伊繆諾金公司 | 苯二氮平衍生物 |
| JP7474195B2 (ja) * | 2018-01-12 | 2024-04-24 | イミュノジェン， インコーポレイテッド | 抗体薬物のコンジュゲーション、精製、及び製剤のための方法 |
| GB201803342D0 (en) | 2018-03-01 | 2018-04-18 | Medimmune Ltd | Methods |
| BR112020019465A2 (pt) | 2018-03-28 | 2021-01-12 | Mitsubishi Tanabe Pharma Corporation | Conjugados de fármaco de agentes monoclonais de ligação a cmet e usos dos mesmos |
| GB201806022D0 (en) | 2018-04-12 | 2018-05-30 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| WO2019222130A1 (en) | 2018-05-15 | 2019-11-21 | Immunogen, Inc. | Combination treatment with antibody-drug conjugates and flt3 inhibitors |
| TW202029980A (zh) * | 2018-10-26 | 2020-08-16 | 美商免疫遺傳股份有限公司 | Ｅ ｐ Ｃ Ａ Ｍ 抗體、可活化抗體及免疫偶聯物以及其用途 |
| KR20210099010A (ko) | 2018-11-12 | 2021-08-11 | 이뮤노젠 아이엔씨 | 세포독성 벤조디아제핀 유도체의 제조 방법 |
| MA54228A (fr) | 2018-11-12 | 2021-09-22 | Immunogen Inc | Procédés de préparation de dérivés de benzodiazépine cytotoxiques |
| CN111393502B (zh) * | 2019-01-03 | 2022-04-29 | 北京京东方技术开发有限公司 | 一种类肽及其制备方法和用途 |
| GB201901197D0 (en) | 2019-01-29 | 2019-03-20 | Femtogenix Ltd | G-A Crosslinking cytotoxic agents |
| TW202102506A (zh) | 2019-03-29 | 2021-01-16 | 美商伊繆諾金公司 | 苯二氮平衍生物 |
| CN113766954B (zh) | 2019-04-26 | 2024-09-24 | 伊缪诺金公司 | 喜树碱衍生物 |
| US11535634B2 (en) | 2019-06-05 | 2022-12-27 | Massachusetts Institute Of Technology | Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof |
| US20230173093A1 (en) | 2020-04-10 | 2023-06-08 | Seagen Inc. | Charge variant linkers |
| WO2022112356A1 (en) | 2020-11-25 | 2022-06-02 | Innate Pharma | Treatment of cancer |
| US12030888B2 (en) | 2021-02-24 | 2024-07-09 | Massachusetts Institute Of Technology | Himastatin derivatives, and processes of preparation thereof, and uses thereof |
| EP4308171A1 (en) | 2021-03-18 | 2024-01-24 | Seagen Inc. | Selective drug release from internalized conjugates of biologically active compounds |
| US12036286B2 (en) | 2021-03-18 | 2024-07-16 | Seagen Inc. | Selective drug release from internalized conjugates of biologically active compounds |
| CA3228268A1 (en) | 2021-08-13 | 2023-02-16 | Andrew Brian Hague | Improved methods for preparing cytotoxic benzodiazepine derivatives |
| WO2023227660A1 (en) | 2022-05-25 | 2023-11-30 | Innate Pharma | Nectin-4 binding agents |
| WO2024015830A1 (en) | 2022-07-12 | 2024-01-18 | Cytomx Therapeutics, Inc. | Epcam immunoconjugates and uses thereof |
| TW202409080A (zh) * | 2022-07-26 | 2024-03-01 | 美商沙塔克實驗室股份有限公司 | 用於治療卵巢癌之組合療法 |
| WO2024076973A1 (en) * | 2022-10-04 | 2024-04-11 | Brown University | Compositions and methods of delivering large proteins |
| WO2024129756A1 (en) | 2022-12-13 | 2024-06-20 | Seagen Inc. | Site-specific engineered cysteine antibody drug conjugates |
Family Cites Families (128)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU11248A1 (ru) | 1927-03-29 | 1929-09-30 | В.С. Григорьев | Способ очистки антрацена |
| US3453266A (en) | 1966-03-14 | 1969-07-01 | American Home Prod | 1,2,5-benzothiadiazepine 1,1-dioxides |
| US3506646A (en) | 1966-06-27 | 1970-04-14 | American Home Prod | Process for the preparation of 7h-pyrido (1,2-b)(1,2,5)benzothiadiazepine 5,5 - dioxides and pyrrolo(1,2-b)(1,2,5)benzothiadiazepine 5,5-dioxides |
| US3860600A (en) | 1972-07-10 | 1975-01-14 | Sterling Drug Inc | Octahydropyrrido{8 2,1-c{9 {8 1,4{9 benzodiazepines |
| US3763183A (en) | 1972-07-10 | 1973-10-02 | Sterling Drug Inc | 1,2,3,10,11,11a-hexahydro-5h-pyrrolo (2,1-c)(1,4)benzodiazepines |
| US3875162A (en) | 1973-07-26 | 1975-04-01 | Squibb & Sons Inc | Certain 6H-pyrimido{8 1,2-c{9 {8 1,3,5{9 benzothiadiaza compounds |
| US4003905A (en) | 1974-12-11 | 1977-01-18 | E. R. Squibb & Sons, Inc. | Diels-alder adducts of benzdiazepines |
| US4342771A (en) | 1981-01-02 | 1982-08-03 | Pfizer Inc. | Hypoglycemic 5-substituted oxazolidine-2,4-diones |
| JPS57131791A (en) | 1980-12-31 | 1982-08-14 | Fujisawa Pharmaceut Co Ltd | Benzodiazepine derivative and its preparation |
| US4444688A (en) | 1981-05-11 | 1984-04-24 | Ciba-Geigy Corporation | Imidazobenzothiadiazepines |
| US4678784A (en) | 1984-04-11 | 1987-07-07 | Mcneilab, Inc. | Method for the treatment of LHRH diseases and conditions |
| JP2920385B2 (ja) | 1988-08-18 | 1999-07-19 | 武田薬品工業株式会社 | １，２，５‐ベンゾチアジアゼピン誘導体，その製造法および用途 |
| GB8827305D0 (en) | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| ES2313867T3 (es) | 1991-12-02 | 2009-03-16 | Medical Research Council | Produccion de anticuerpos anti-auto de repertorios de segmentos de anticuerpo expresados en la superficie de fagos. |
| GB9205051D0 (en) | 1992-03-09 | 1992-04-22 | Cancer Res Campaign Tech | Pyrrolobenzodiazepine derivatives,their preparation,and compositions containing them |
| ES2149768T3 (es) | 1992-03-25 | 2000-11-16 | Immunogen Inc | Conjugados de agentes enlazantes de celulas derivados de cc-1065. |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US5455258A (en) | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
| JPH08176070A (ja) | 1994-12-19 | 1996-07-09 | Mitsubishi Chem Corp | ジデプシド誘導体及びｐｉ３キナーゼ阻害剤 |
| JPH08175990A (ja) | 1994-12-19 | 1996-07-09 | Mitsubishi Chem Corp | Ｐｉ３キナーゼ阻害剤とその製造法 |
| US5863949A (en) | 1995-03-08 | 1999-01-26 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
| US5861510A (en) | 1995-04-20 | 1999-01-19 | Pfizer Inc | Arylsulfonyl hydroxamic acid derivatives as MMP and TNF inhibitors |
| GB9521987D0 (en) | 1995-10-26 | 1996-01-03 | Ludwig Inst Cancer Res | Phosphoinositide 3-kinase modulators |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| ES2183905T3 (es) | 1995-12-20 | 2003-04-01 | Hoffmann La Roche | Inhibidores de metaloproteasa de matriz. |
| EP0880508B1 (en) | 1996-02-13 | 2003-04-16 | AstraZeneca AB | Quinazoline derivatives as vegf inhibitors |
| IL125954A (en) | 1996-03-05 | 2003-06-24 | Zeneca Ltd | Quinazoline derivatives, processes for their preparation, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments having an antiangiogenic and/or vascular permeability reducing effect |
| EP0818442A3 (en) | 1996-07-12 | 1998-12-30 | Pfizer Inc. | Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor |
| EP0923585B1 (en) | 1996-07-18 | 2002-05-08 | Pfizer Inc. | Phosphinate based inhibitors of matrix metalloproteases |
| CN1228083A (zh) | 1996-08-23 | 1999-09-08 | 美国辉瑞有限公司 | 芳基磺酰氨基异羟肟酸衍生物 |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| WO1998030566A1 (en) | 1997-01-06 | 1998-07-16 | Pfizer Inc. | Cyclic sulfone derivatives |
| NZ336840A (en) | 1997-02-03 | 2001-01-26 | Pfizer Prod Inc | Arylsulfonylamino hydroxamic acid derivatives useful in the treatment of tumor necrosis factor and matrix metalloproteinase mediated diseases |
| JP2000507975A (ja) | 1997-02-07 | 2000-06-27 | ファイザー・インク | Ｎ−ヒドロキシ−β−スルホニルプロピオンアミド誘導体類及びそれらのマトリックスメタロプロテイナーゼ阻害薬としての使用 |
| IL131123A0 (en) | 1997-02-11 | 2001-01-28 | Pfizer | Arylsulfonyl hydroxamic acid derivatives |
| WO1998035985A1 (en) | 1997-02-12 | 1998-08-20 | The Regents Of The University Of Michigan | Protein markers for lung cancer and use thereof |
| WO1999006587A2 (en) | 1997-08-01 | 1999-02-11 | Morphosys Ag | Novel method and phage for the identification of nucleic acid sequences encoding members of a multimeric (poly)peptide complex |
| NZ502309A (en) | 1997-08-08 | 2002-02-01 | Pfizer Prod Inc | Aryloxyarylsulfonylamino hydroxamic acid derivatives and pharmaceutical use |
| GB9725782D0 (en) | 1997-12-05 | 1998-02-04 | Pfizer Ltd | Therapeutic agents |
| GB9801690D0 (en) | 1998-01-27 | 1998-03-25 | Pfizer Ltd | Therapeutic agents |
| JP4462654B2 (ja) | 1998-03-26 | 2010-05-12 | ソニー株式会社 | 映像素材選択装置及び映像素材選択方法 |
| PA8469401A1 (es) | 1998-04-10 | 2000-05-24 | Pfizer Prod Inc | Derivados biciclicos del acido hidroxamico |
| PA8469501A1 (es) | 1998-04-10 | 2000-09-29 | Pfizer Prod Inc | Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico |
| US6156746A (en) | 1998-08-25 | 2000-12-05 | Bristol-Myers Squibb Company | 1,2,5-benzothiadiazepine-1,1-dioxides with n-2 imidazolylalkyl substituents |
| ES2244210T3 (es) | 1998-08-27 | 2005-12-01 | Spirogen Limited | Pirrolobenzodiazepinas. |
| GB9818731D0 (en) | 1998-08-27 | 1998-10-21 | Univ Portsmouth | Compounds |
| PT1004578E (pt) | 1998-11-05 | 2004-06-30 | Pfizer Prod Inc | Derivados hidroxamida do acido 5-oxo-pirrolidino-2-carboxilico |
| US7115396B2 (en) | 1998-12-10 | 2006-10-03 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| AU763618B2 (en) | 1999-02-10 | 2003-07-31 | Astrazeneca Ab | Quinazoline derivatives as angiogenesis inhibitors |
| FR2800507B1 (fr) | 1999-10-27 | 2002-01-04 | Valeo Systemes Dessuyage | Commutateur electrique rotatif, notamment pour un moteur d'essuie-glace de vehicule automobile |
| JP3287409B2 (ja) | 1999-10-28 | 2002-06-04 | 日本精工株式会社 | ロック機構付シートベルト用リトラクターを備えたシートベルト装置 |
| PT1244647E (pt) | 1999-11-05 | 2006-10-31 | Astrazeneca Ab | Derivados de quinazolina como inibidores de vegf |
| WO2001038318A1 (en) | 1999-11-24 | 2001-05-31 | Immunogen, Inc. | Cytotoxic agents comprising taxanes and their therapeutic use |
| DE122010000004I1 (de) | 2000-02-15 | 2010-04-15 | Sugen Inc | Pyrrol substituierte indolin-2-on protein kinase inhibitoren |
| JP2001247477A (ja) | 2000-03-03 | 2001-09-11 | Teikoku Hormone Mfg Co Ltd | 抗腫瘍剤 |
| US6403588B1 (en) | 2000-04-27 | 2002-06-11 | Yamanouchi Pharmaceutical Co., Ltd. | Imidazopyridine derivatives |
| US6608053B2 (en) | 2000-04-27 | 2003-08-19 | Yamanouchi Pharmaceutical Co., Ltd. | Fused heteroaryl derivatives |
| MXPA02011727A (es) * | 2000-05-26 | 2003-10-24 | Johnson & Johnson | Peptidos neuroprotectores. |
| WO2002020565A2 (en) | 2000-09-08 | 2002-03-14 | Universität Zürich | Collections of repeat proteins comprising repeat modules |
| ATE290882T1 (de) | 2001-01-16 | 2005-04-15 | Glaxo Group Ltd | Pharmazeutische mischung gegen krebs, die ein 4- chinazolinamin in kombination mit paclitaxel, carboplatin or vinorelbine enthält |
| US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
| CA2454976C (en) | 2001-07-26 | 2011-05-10 | Santen Pharmaceutical Co., Ltd. | Therapeutic agent for glaucoma comprising compound having pi3 kinase inhibitory action as active ingredient |
| US6703414B2 (en) | 2001-09-14 | 2004-03-09 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Device and method for treating restenosis |
| US6908932B2 (en) | 2001-10-24 | 2005-06-21 | Iconix Pharmaceuticals, Inc. | Modulators of phosphoinositide 3-kinase |
| WO2003034997A2 (en) | 2001-10-24 | 2003-05-01 | Iconix Pharmaceuticals, Inc. | Modulators of phosphoinositide 3-kinase |
| EP1444010A2 (en) | 2001-10-30 | 2004-08-11 | Pharmacia Corporation | Heteroaromatic carboxamide derivatives for the treatment of inflammation |
| US6716821B2 (en) | 2001-12-21 | 2004-04-06 | Immunogen Inc. | Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same |
| US6756397B2 (en) | 2002-04-05 | 2004-06-29 | Immunogen, Inc. | Prodrugs of CC-1065 analogs |
| GB0209467D0 (en) | 2002-04-25 | 2002-06-05 | Astrazeneca Ab | Chemical compounds |
| US7538195B2 (en) * | 2002-06-14 | 2009-05-26 | Immunogen Inc. | Anti-IGF-I receptor antibody |
| RS115904A (en) | 2002-07-10 | 2006-12-15 | Applied Research Systems Ars Holding N.V. | Azolidinone-vinyl fused benzene derivatives |
| EP1531813A1 (en) | 2002-07-10 | 2005-05-25 | Applied Research Systems ARS Holding N.V. | Use of compounds for increasing spermatozoa motility |
| US20040092561A1 (en) | 2002-11-07 | 2004-05-13 | Thomas Ruckle | Azolidinone-vinyl fused -benzene derivatives |
| EP1534674A4 (en) | 2002-08-02 | 2007-11-28 | Immunogen Inc | CYTOTOXIC AGENTS CONTAINING NEW, EFFECTIVE TAXANES AND THEIR THERAPEUTIC USE |
| AU2003259163B2 (en) | 2002-08-16 | 2008-07-03 | Immunogen, Inc. | Cross-linkers with high reactivity and solubility and their use in the preparation of conjugates for targeted delivery of small molecule drugs |
| AU2003255845A1 (en) | 2002-08-22 | 2004-03-11 | Piramed Limited | Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents |
| WO2004043344A2 (en) | 2002-11-07 | 2004-05-27 | Immunogen, Inc. | Anti-cd33 antibodies and method for treatment of acute myeloid leukemia using the same |
| FR2850654A1 (fr) | 2003-02-03 | 2004-08-06 | Servier Lab | Nouveaux derives d'azepines tricycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| ATE413407T1 (de) | 2003-03-31 | 2008-11-15 | Council Scient Ind Res | Pyrrolo(2,1-c)(1,4)benzodiazepin-dimere als antitumormittel und verfahren dafür |
| RU2338747C2 (ru) | 2003-03-31 | 2008-11-20 | Каунсил Оф Сайентифик Энд Индастриал Рисерч | ДИМЕРЫ ПИРРОЛО [2, 1-c][1, 4] БЕНЗОДИАЗЕПИНА В КАЧЕСТВЕ ПРОТИВООПУХОЛЕВЫХ СРЕДСТВ И СПОСОБ ИХ ПОЛУЧЕНИЯ |
| RU2314309C2 (ru) * | 2003-03-31 | 2008-01-10 | Каунсил Оф Сайентифик Энд Индастриал Рисерч | Пирроло [2.1-c][1.4] бензодиазепины, способ их получения и фармацевтическая композиция на их основе |
| DE60326060D1 (de) | 2003-03-31 | 2009-03-19 | Council Scient Ind Res | Nichtvernetzende pyrroloä2,1-cüä1,4übenzodiazepine als potentielle antitumor-agentien und ihre herstellung |
| US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
| US7276497B2 (en) | 2003-05-20 | 2007-10-02 | Immunogen Inc. | Cytotoxic agents comprising new maytansinoids |
| ATE516288T1 (de) | 2003-10-22 | 2011-07-15 | Us Gov Health & Human Serv | Pyrrolobenzodiazepinderivate, zusammensetzungen, die diese enthalten, und damit in zusammenhang stehende verfahren |
| GB0404578D0 (en) | 2004-03-01 | 2004-04-07 | Spirogen Ltd | Pyrrolobenzodiazepines |
| JP5166861B2 (ja) | 2004-03-09 | 2013-03-21 | スピロゲン リミティッド | ピロロベンゾジアゼピン |
| GB0410725D0 (en) | 2004-05-13 | 2004-06-16 | Spirogen Ltd | Pyrrolobenzodiazepine therapeutic agents |
| EP2286844A3 (en) | 2004-06-01 | 2012-08-22 | Genentech, Inc. | Antibody-drug conjugates and methods |
| NZ553500A (en) | 2004-09-23 | 2009-11-27 | Genentech Inc Genentech Inc | Cysteine engineered antibodies and conjugates withCysteine engineered antibodies and conjugates with a free cysteine amino acid in the heavy chain a free cysteine amino acid in the heavy chain |
| GB0423653D0 (en) | 2004-10-25 | 2004-11-24 | Piramed Ltd | Pharmaceutical compounds |
| AU2005316844A1 (en) | 2004-11-29 | 2006-06-22 | Seattle Genetics, Inc. | Engineered antibodies and immunoconjugates |
| US7301019B2 (en) | 2005-01-21 | 2007-11-27 | Immunogen, Inc. | Method for the preparation of maytansinoid esters |
| US20060182750A1 (en) | 2005-02-11 | 2006-08-17 | Immunogen, Inc. | Process for preparing stable drug conjugates |
| US8846577B2 (en) | 2005-07-08 | 2014-09-30 | University Of Zurich | Phage display using cotranslational translocation of fusion polypeptides |
| US7772485B2 (en) | 2005-07-14 | 2010-08-10 | Konarka Technologies, Inc. | Polymers with low band gaps and high charge mobility |
| ITRM20050416A1 (it) | 2005-08-03 | 2007-02-04 | Uni Degli Studi Di Roma Tor Vergata | Derivati delle benzodiazepine e loro usi in campo medico. |
| WO2007021674A2 (en) | 2005-08-09 | 2007-02-22 | Millennium Pharmaceuticals, Inc. | Method of acylating maytansinol with chiral amino acids |
| EP1928503B1 (en) | 2005-08-24 | 2012-10-03 | ImmunoGen, Inc. | Process for preparing maytansinoid antibody conjugates |
| WO2007039752A1 (en) | 2005-10-05 | 2007-04-12 | Spirogen Limited | Alkyl 4- [4- (5-oxo-2, 3, 5, 11a-tetrahyd0-5h-pyrr0l0 [2, 1-c] [1, 4] benzodiazepine-8-yloxy) -butyrylamino]-1h-pyrrole-2-carboxylate derivatives and related compounds for the treatment of a proliferative disease |
| GB0520657D0 (en) | 2005-10-11 | 2005-11-16 | Ludwig Inst Cancer Res | Pharmaceutical compounds |
| RS52060B (en) | 2006-01-25 | 2012-04-30 | Sanofi | CYTOTOXIC AGENTS CONTAINING NEW TOMAIMYCIN DERIVATIVES |
| JP2009526778A (ja) | 2006-02-13 | 2009-07-23 | カウンシル オブ サイエンティフィク アンド インダストリアル リサーチ | 抗腫瘍剤としてのビス−ピロロ［２，１−ｃ］［１，４］ベンゾジアゼピン−アントラキノン抱合体およびその製造方法 |
| EP2447282B1 (en) | 2006-05-30 | 2016-01-27 | Genentech, Inc. | Anti-CD22 Antibodies, their Immunoconjugates and uses thereof |
| EP1864682A1 (en) | 2006-06-09 | 2007-12-12 | Sanofi-Aventis | Leptomycin derivatives |
| WO2008141044A2 (en) | 2007-05-08 | 2008-11-20 | Genentech, Inc. | Cysteine engineered anti-muc16 antibodies and antibody drug conjugates |
| PL2019104T3 (pl) * | 2007-07-19 | 2014-03-31 | Sanofi Sa | Środki cytotoksyczne obejmujące nowe pochodne tomaymycyny i ich zastosowanie terapeutyczne |
| ATE543826T1 (de) * | 2007-08-01 | 2012-02-15 | Council Scient Ind Res | Als selektive antitumormittel geeignete pyrroloä2,1-cüä1,4übenzodiazepinglycosid-prodru s |
| US20100003641A1 (en) | 2007-08-15 | 2010-01-07 | Hansen John P | Dental crown system |
| WO2009040338A1 (en) | 2007-09-24 | 2009-04-02 | University Of Zürich | Designed armadillo repeat proteins |
| SG189817A1 (en) | 2008-04-30 | 2013-05-31 | Immunogen Inc | Potent conjugates and hydrophilic linkers |
| LT2281006T (lt) | 2008-04-30 | 2017-11-27 | Immunogen, Inc. | Skersinių jungčių linkeriai ir jų panaudojimas |
| GB0819095D0 (en) * | 2008-10-17 | 2008-11-26 | Spirogen Ltd | Pyrrolobenzodiazepines |
| SG173152A1 (en) | 2009-02-05 | 2011-08-29 | Immunogen Inc | Novel benzodiazepine derivatives |
| WO2010093627A2 (en) | 2009-02-12 | 2010-08-19 | Centocor Ortho Biotech Inc. | Fibronectin type iii domain based scaffold compositions, methods and uses |
| CA2748414A1 (en) * | 2009-04-24 | 2010-10-28 | F. Hoffmann-La Roche Ag | Inhibitors of bruton's tyrosine kinase |
| WO2010134437A1 (ja) | 2009-05-18 | 2010-11-25 | Nishiyama Shuhei | 仮想単一メモリストレージ上におけるメタ情報共有型分散データベース・システム |
| EP2486023A4 (en) * | 2009-10-06 | 2014-05-07 | Immunogen Inc | EFFICIENT CONJUGATES AND HYDROPHILIC BINDER |
| UA123257C2 (uk) | 2010-02-24 | 2021-03-10 | Іммуноджен, Інк. | Виділений поліпептид, що кодує антитіло до рецептора фолієвої кислоти 1 |
| KR101671360B1 (ko) | 2010-04-15 | 2016-11-01 | 시애틀 지네틱스, 인크. | 표적화된 피롤로벤조디아제핀 접합체 |
| JP5972864B2 (ja) | 2010-04-15 | 2016-08-17 | メディミューン リミテッド | ピロロベンゾジアゼピン及びそれらのコンジュゲート |
| WO2011130616A1 (en) | 2010-04-15 | 2011-10-20 | Spirogen Limited | Pyrrolobenzodiazepines used to treat proliferative diseases |
| EP2640727B1 (en) | 2010-11-17 | 2015-05-13 | Genentech, Inc. | Alaninyl maytansinol antibody conjugates |
| EP3666289A1 (en) * | 2011-02-15 | 2020-06-17 | ImmunoGen, Inc. | Cytotoxic benzodiazepine derivatives |
| EP2887965A1 (en) * | 2012-08-22 | 2015-07-01 | ImmunoGen, Inc. | Cytotoxic benzodiazepine derivatives |
| JP2015202619A (ja) * | 2014-04-14 | 2015-11-16 | 独立行政法人 国立印刷局 | 凹版版面 |
-
2012
- 2012-02-15 EP EP20153273.6A patent/EP3666289A1/en active Pending
- 2012-02-15 KR KR1020197012764A patent/KR20190051081A/ko not_active IP Right Cessation
- 2012-02-15 ES ES12705600.0T patent/ES2567418T3/es active Active
- 2012-02-15 RS RS20160186A patent/RS54667B1/en unknown
- 2012-02-15 DK DK12705600.0T patent/DK2675479T3/en active
- 2012-02-15 CN CN202110553208.6A patent/CN113896731A/zh active Pending
- 2012-02-15 SG SG10201601046QA patent/SG10201601046QA/en unknown
- 2012-02-15 KR KR1020137024312A patent/KR20140010076A/ko not_active Application Discontinuation
- 2012-02-15 PT PT12705761T patent/PT2675480T/pt unknown
- 2012-02-15 US US13/397,195 patent/US8765740B2/en active Active
- 2012-02-15 CN CN201280014480.6A patent/CN103687623B/zh active Active
- 2012-02-15 AU AU2012231640A patent/AU2012231640B2/en active Active
- 2012-02-15 WO PCT/US2012/025292 patent/WO2012112708A1/en active Application Filing
- 2012-02-15 CN CN201280018499.8A patent/CN103702686B/zh active Active
- 2012-02-15 MX MX2013009420A patent/MX346635B/es active IP Right Grant
- 2012-02-15 MX MX2013009417A patent/MX343337B/es active IP Right Grant
- 2012-02-15 EP EP12705600.0A patent/EP2675479B1/en active Active
- 2012-02-15 PL PL12705600.0T patent/PL2675479T3/pl unknown
- 2012-02-15 ME MEP-2016-59A patent/ME02381B/me unknown
- 2012-02-15 KR KR1020197018885A patent/KR20190089048A/ko not_active Application Discontinuation
- 2012-02-15 MY MYPI2013002960A patent/MY183977A/en unknown
- 2012-02-15 RU RU2017131902A patent/RU2748733C2/ru active
- 2012-02-15 BR BR112013020540-7A patent/BR112013020540B1/pt active IP Right Grant
- 2012-02-15 RU RU2017117634A patent/RU2017117634A/ru unknown
- 2012-02-15 JP JP2013554574A patent/JP5826863B2/ja active Active
- 2012-02-15 EP EP12707186.8A patent/EP2675481A1/en not_active Withdrawn
- 2012-02-15 CA CA3034596A patent/CA3034596C/en active Active
- 2012-02-15 ES ES12705761T patent/ES2717657T3/es active Active
- 2012-02-15 EP EP12705761.0A patent/EP2675480B1/en active Active
- 2012-02-15 EP EP18213740.6A patent/EP3498303A1/en not_active Withdrawn
- 2012-02-15 US US13/984,762 patent/US9534000B2/en active Active
- 2012-02-15 SG SG2013053632A patent/SG191955A1/en unknown
- 2012-02-15 WO PCT/US2012/025252 patent/WO2012128868A1/en active Application Filing
- 2012-02-15 TW TW101104846A patent/TWI617555B/zh active
- 2012-02-15 UA UAA201310945A patent/UA120696C2/uk unknown
- 2012-02-15 IL IL279304A patent/IL279304B/en unknown
- 2012-02-15 HU HUE12705761A patent/HUE043976T2/hu unknown
- 2012-02-15 KR KR1020207035392A patent/KR20200141534A/ko not_active Application Discontinuation
- 2012-02-15 WO PCT/US2012/025257 patent/WO2012112687A1/en active Application Filing
- 2012-02-15 US US13/397,205 patent/US9353127B2/en active Active
- 2012-02-15 KR KR1020207035369A patent/KR20200140939A/ko not_active Application Discontinuation
- 2012-02-15 SI SI201231578T patent/SI2675480T1/sl unknown
- 2012-02-15 CA CA2825919A patent/CA2825919C/en active Active
- 2012-02-15 HU HUE12705600A patent/HUE028736T2/en unknown
- 2012-02-15 RS RS20190394A patent/RS58620B1/sr unknown
- 2012-02-15 KR KR1020137023868A patent/KR20140010067A/ko not_active Application Discontinuation
- 2012-02-15 SI SI201230460T patent/SI2675479T1/sl unknown
- 2012-02-15 CN CN201710188948.8A patent/CN107335061B/zh active Active
- 2012-02-15 BR BR112013019913-0A patent/BR112013019913B1/pt active IP Right Grant
- 2012-02-15 RU RU2013141829A patent/RU2631498C2/ru active
- 2012-02-15 SG SG2013053780A patent/SG191965A1/en unknown
- 2012-02-15 RU RU2013142179A patent/RU2621035C2/ru active
- 2012-02-15 AU AU2012217719A patent/AU2012217719B2/en active Active
- 2012-02-15 PL PL12705761T patent/PL2675480T3/pl unknown
- 2012-02-15 SG SG10202007640VA patent/SG10202007640VA/en unknown
- 2012-02-15 JP JP2013554575A patent/JP6049642B2/ja active Active
- 2012-02-15 MY MYPI2013002959A patent/MY169448A/en unknown
- 2012-02-15 IL IL293365A patent/IL293365A/en unknown
- 2012-02-15 EP EP16150802.3A patent/EP3053600B1/en active Active
- 2012-02-15 LT LTEP12705761.0T patent/LT2675480T/lt unknown
- 2012-02-15 CA CA2824864A patent/CA2824864C/en active Active
- 2012-02-15 DK DK12705761.0T patent/DK2675480T3/en active
- 2012-02-15 CA CA3110544A patent/CA3110544A1/en not_active Abandoned
- 2012-02-15 CN CN201610950438.5A patent/CN107050468A/zh active Pending
-
2013
- 2013-03-14 US US13/827,355 patent/US8889669B2/en active Active
- 2013-07-17 ZA ZA2013/05386A patent/ZA201305386B/en unknown
- 2013-08-14 IL IL227963A patent/IL227963A/en active IP Right Grant
- 2013-08-14 IL IL227964A patent/IL227964A/en active IP Right Grant
- 2013-12-27 HK HK13114335.0A patent/HK1186686A1/zh unknown
-
2014
- 2014-10-10 US US14/512,059 patent/US9169272B2/en active Active
-
2015
- 2015-09-09 US US14/849,270 patent/US9434748B2/en not_active Expired - Fee Related
- 2015-10-14 JP JP2015202619A patent/JP6216356B2/ja not_active Expired - Fee Related
-
2016
- 2016-02-05 AU AU2016200752A patent/AU2016200752B2/en not_active Ceased
- 2016-02-15 HR HRP20160164TT patent/HRP20160164T1/hr unknown
- 2016-03-24 CY CY20161100252T patent/CY1117340T1/el unknown
- 2016-04-08 SM SM201600099T patent/SMT201600099B/xx unknown
- 2016-04-13 US US15/097,979 patent/US9868791B2/en not_active Expired - Fee Related
- 2016-07-27 US US15/221,255 patent/US9840564B2/en active Active
-
2017
- 2017-07-10 US US15/645,597 patent/US10179818B2/en active Active
- 2017-07-14 ZA ZA2017/04808A patent/ZA201704808B/en unknown
- 2017-08-15 US US15/677,846 patent/US10364294B2/en not_active Expired - Fee Related
- 2017-08-17 IL IL254055A patent/IL254055A0/en active IP Right Grant
- 2017-08-23 IL IL254128A patent/IL254128A0/en unknown
- 2017-09-22 JP JP2017182007A patent/JP6526138B2/ja active Active
- 2017-11-28 AU AU2017268554A patent/AU2017268554B2/en not_active Ceased
-
2018
- 2018-11-30 US US16/205,609 patent/US10570212B2/en not_active Ceased
-
2019
- 2019-03-22 CY CY20191100338T patent/CY1121532T1/el unknown
- 2019-03-25 HR HRP20190576TT patent/HRP20190576T1/hr unknown
- 2019-04-24 JP JP2019082629A patent/JP6703632B2/ja active Active
- 2019-11-13 AU AU2019264595A patent/AU2019264595A1/en not_active Abandoned
-
2020
- 2020-05-08 JP JP2020082654A patent/JP2020143102A/ja active Pending
-
2021
- 2021-05-10 US US17/316,241 patent/USRE49918E1/en active Active
- 2021-10-13 JP JP2021167884A patent/JP2022009073A/ja active Pending
-
2023
- 2023-11-29 JP JP2023201247A patent/JP2024026207A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014521591A5 (US07714131-20100511-C00001.png) | ||
| RU2017131902A (ru) | Цитотоксические производные бензодиазепина | |
| JP2013542958A5 (US07714131-20100511-C00001.png) | ||
| RU2015103852A (ru) | Новые производные бензодиазепина | |
| JP2012516896A5 (US07714131-20100511-C00001.png) | ||
| ES2703151T3 (es) | Conjugados de anticuerpos de pirrolobenzodiazepinas | |
| ES2871001T3 (es) | Conjugados de pirrolobenzodiazepinas y anticuerpos | |
| CN118434765A (zh) | Bcma单克隆抗体和抗体-药物偶联物 | |
| ES2670937T3 (es) | Conjugados de anticuerpo-pirrolobenzodiazepina | |
| JP2023011799A (ja) | 抗体－薬物コンジュゲート | |
| ES2660029T3 (es) | Conjugados de anticuerpo-pirrolobenzodiazepinas | |
| ES2680153T3 (es) | Conjugados de anticuerpos anti-PSMA-pirrolobenzodiazepinas | |
| RU2503687C2 (ru) | Сшивающие реагенты и их применение | |
| RU2018146948A (ru) | Антитела к в7-н3 и конъюгаты антитела и лекарственного средства | |
| US20230023537A1 (en) | Delivery systems for controlled drug release | |
| JP2017528467A5 (US07714131-20100511-C00001.png) | ||
| TW201811793A (zh) | 吡咯並苯並二氮呯類和彼等之共軛物類 | |
| EA034138B1 (ru) | Цитотоксические бензодиазепиновые производные | |
| CN106414465B (zh) | 带电荷链接体及其在共轭反应上的应用 | |
| JP2018516243A5 (US07714131-20100511-C00001.png) | ||
| HRP20200032T1 (hr) | Antitijelo lijek konjugati | |
| ES2690067T9 (es) | Conjugados de anticuerpos anti-PSMA-Pirrolobenzodiazepinas | |
| CN115443134A (zh) | 细胞结合分子与喜树碱类似物的偶联物 | |
| WO2017214462A4 (en) | Anti-cd98 antibodies and antibody drug conjugates | |
| JP2021521172A (ja) | 抗腫瘍剤としてのピロロベンゾジアゼピン及びその複合体 |
